{
  "docId": "019dd923-5fec-763b-95d0-6c2b37f81466",
  "docSlug": "bi-9523b367be63361f",
  "documentTitle": "3T Biosciences 27-slide pitch deck to raise $40M Series A",
  "authorId": "Pitchdecks",
  "authorName": "3T Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.6,
  "pageNumber": 19,
  "pageCount": 27,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses two line charts to demonstrate the efficacy and specificity of engineered TCRs compared to a benchmark.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "paragraph",
    "line_chart"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95d0-6c2b37f81466/19",
  "deckHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466#slide-19",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "3T TCR’s engineered for specificity with TRACE-outputs show equivalent potency in vitro and increased target specificity by in vitro T cell killing assays",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-c0aa-76ce-98c0-06e134616267",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.24,
        "y": 0.045
      },
      "kind": "chart",
      "text": "WT A375 (target+)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "528878ea-fa58-4384-a670-5b82cabac7a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.62,
        "y": 0.045
      },
      "kind": "chart",
      "text": "A375 target- (CRISPR KO)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c13a0d83-bfb0-44f3-bfa2-962a6f1b019d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Cytotoxicity",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-c0aa-76ce-98c0-08326104544a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.06,
        "y": 0.038
      },
      "kind": "paragraph",
      "text": "3T TCR's engineered for specificity with TRACE-outputs show equivalent potency in vitro and increased target specificity by in vitro T cell killing assays",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8436bfe-9adf-4bfa-9cd5-24f780e37705",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "title",
      "text": "AACR Data: 3T TCRs show Equal Potency and Increased Target Specificity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6093e433-99ea-4e8d-be6e-6b1e984a1727",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "3T's Cross Reactivity Profiling Increases Probability of Success and Optimal Product Profile in the Clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d517a23-d5e5-4c88-9f54-86821fb68ba0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 17,
      "beatId": "73a34dcb-2314-48dd-b4f8-88d5ee73c244",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 17-19 agitate the problem by highlighting the limitations of current immunotherapies and the need for better solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b4672338-76bf-4840-8e57-d1ec2e6417b2",
      "evidence": "The deck highlights the significant unmet need in solid tumor cancers and the limitations of current immunotherapies",
      "position": 0,
      "objective": "Highlight the cost of inaction in solid tumor cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}